Perhaps someone can spread the word....say to that other forum...Re—-/WS....It seems my account is too new....
Amarin ticker (AMRN). Maker of Vascepa.
The company name is thought to mean everlasting or from the sea depending on who you believe. Both are quite right. Vascepa is icosapent ethyl... a purified and modified omega-3 that when taken on top of a statin (think Lipitor) basically cuts your risk of dying, having a heart attack, or a stroke by 25%.
Sounds good right? Lipitor was the best selling drug of all time until Humira. Yet it started out slow in its first year just like Vascepa...and without a pandemic. Now we have generic statins with hundreds of millions of patients worldwide taking daily. Lipitor had its run though. Just ask Pfizer. And it still sells tons of cabbage. But there is only one Vascepa that reduces your triglycerides and reduces your cardiovascular risk. Funny thing is...it’s not the triglyceride reduction that bestows the benefit......more later......Less stokes, stents, open heart bypass surgery....and DEATH!!!
There are many different oils, or properly called fatty acids, in those over the counter omega-3’s you may take. But only this particular one has been shown in double blind randomized trials to Work. At least two of the others, DHA and DPA likely actually hurt!!!!! No one really knows why. We think it’s it’s powerful anti-inflammatory properties of 100% icosapent ethyl or EPA (Vascepa).
Think.....“it coats the insides of your arteries and puts out the fire connected to the ticking time bomb”. For reference see the New England Journal of Medicine article from 2018 called the REDUCIT study. Also see the EVAPORATE study from 2020 that showed coronary artery plaque regression. That’s right...Vascepa likely is liquid draino for your coronaries!!!!
Let that sink in a minute. There are two large Covid-19 studies reporting in first half of this year called MITIGATe and PREPARE—IT. Prepare-It will likely read out end of Feb. Mitigate interim around May. The thought is the anti inflammatory power of V helps. One Canadian study presented in December at the national lipid association showed statistics better than Remdesivir. Vascepa may snuff out the cytokines storm that kills you from Covid!!!!
It may also disrupt the viruses transmissibility as covid is wrapped in...you guessed it...fatty acids and lipids.
Let that sink in a minute.
Amarin won the FDA approval for CVT reduction in Dec 2019. She hit $26 soon after. March 30, 2020 a Nevada judge was hoodwinked into overturning the patents of the original label for treating only patients with triglycerides over 500 to treat pancreatitis, thus potentially allowing generics to entreat themselves to AMARIN’s three billion a year US market (when mature..we only a year in). More than 90% of Vascepa scripts are for the cardiovascular indication...not for the skinny label treatment of triglycerides...for pancreatitis. The money is in the CVT risk reduction...i.e...the statin patients world wide. AMARIN spent nearly a billion dollars bringing this indication to market. And now generics want to try and steal it all. So far so good except for the market perception. AMARIN claims to have the API sources secured.
Thus far there is one generic made by HICKMA. The company that won the court case. Litigation is still ongoing and AMARIN is now suing them for infringing on the CVT indication patents that are still quite valid. Damages could be huge!!!!
Amarin won EU recommendation for the CVT indication in Europe on Friday and can start marketing likely by April. Europe’s market is maybe 50% larger than the US. Thus far Amarin has maintained the US market with Hickma currently holding 6% of the market. Yet the stock cratered from $26 to $4 in March. Today she sits just over $8. The drop was likely because all thought the US market was completely toast. Clearly it is not 4 months post generic launch. Add to this that Lovaza still makes up a large part of the prescription omega-3 market and there really is no good reason to ever take Lovaza now that Vascepa is here, and you can see that AMRN’s revenues are going to be huge. Last year was unaudited $611 mill. 1 billion tax loss carry over. 550 million in cash or investments. No debt. Zero debt...... Price currently $8.25
There seems to be a lot of selling between entities to ladder step her down almost daily since the March debacle. Despite that she has doubled. That the company updated its “Change of control” package and policy in an 8-k filed this Friday, one day after European approval recommendation could mean a Buy Out is imminent. Amarin was built for a buy out. She a one drug pony, but the drug is a doozy. I truly believe US can generate $1 bill in sales. EU $3 billion a year. Approval in China by Amarin partner could generate $5 bill a year but AMARIN gets a straight high teens royalty from Eddingpharm ( the Chinese owned partner)
Long story short, this drug saves lives and WILL make a lot of money. Last I looked there were 22 mill shares short. With float of 386 million but much more than half the float is locked up. The daily shenanigans need to stop. The respect and eyes of the world needs to be on Vascepa!!!! It’s truly a lifesaver with untold uses and benefits. I honestly believe there is a huge covid benefit to being on Vascepa and we will soon know. Let’s see what happens when the PEOPLE get behind a company that has been screwed over and over yet gets back up again because the science of the drug is a once in 50 years proven scientific discovery. I bet she deservedly goes gangbusters and MOST IMPORTANTLY ....then HOLDS her gains. There won’t be a find a chair when the music stops here.
Your consideration is appreciated.
